Drug General Information
Drug ID
D01JFM
Former ID
DIB001402
Drug Name
AC-170
Drug Type
Small molecular drug
Indication Allergic conjunctivitis [ICD9: 204.0, 372.0, 372.14, 995.3; ICD10:C91.0, H10, H10.45, T78.4] Phase 3 [524743]
Company
Aciex Therapeutics Inc
Formula
C6H6BrNO
Canonical SMILES
C1=CC(=NC=C1Br)CO
InChI
1S/C6H6BrNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2
InChIKey
RUCZFWMEACWFER-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Histamine H1 receptor Target Info Antagonist [551442]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Inflammatory mediator regulation of TRP channels
PANTHER Pathway Histamine H1 receptor mediated signaling pathway
Reactome Histamine receptors
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
IL-4 Signaling Pathway
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 524743ClinicalTrials.gov (NCT02132169) A Multi-Center Study Evaluating the Safety of AC-170 0.24%. U.S. National Institutes of Health.
Ref 551442Clinical pipeline report, company report or official report of NicOx SA.